诺和诺德欧股股价下跌11%。公司表示，在试验中，其CagriSema的效果不及礼来的Zepbound。

Group 1 - Novo Nordisk's stock price fell by 11% following the announcement that its CagriSema trial results were less effective compared to Eli Lilly's Zepbound [1] - The company indicated that the performance of CagriSema did not meet expectations in comparison to its competitor's product [1]